Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDItion: Ipatasertib + Darolutamide in Prostate Cancer
NCT04737109Phase 2Terminated
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipatasertib in prostate cancer (PCa) (2 cohorts). Primary endpoint: Pathological Complete Response Rate. Started Jul 2021; status: terminated.
02
Drugs
ipatasertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04737109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737109.